Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002721 · ClinicalTrials.gov registry record · Phase 1
Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00002721: Completed Phase 1 study, sponsored by University of New Mexico.
NCT00002721 is a Phase 1 study that has completed, run by University of New Mexico. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002721, a Phase 1 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.
Interventions
- DRUG doxorubicin hydrochloride
- DRUG estramustine phosphate sodium
- PROCEDURE drug resistance inhibition treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1995-03 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
What the finished NCT00002721 record still lists
NCT00002721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 3 interventions - of which doxorubicin hydrochloride is the first listed.
NCT00002721 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002721 about?
NCT00002721 is a clinical study titled "Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic rec...
What is the current status of trial NCT00002721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 1995-03. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00002721?
The interventions under investigation include: doxorubicin hydrochloride (DRUG), estramustine phosphate sodium (DRUG), drug resistance inhibition treatment (PROCEDURE).
Who is sponsoring clinical trial NCT00002721?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002721's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia